nifedipine er tablet (extended-release)
pro doc limitee - nifedipine - tablet (extended-release) - 60mg - nifedipine 60mg - dihydropyridines
pms-nifedipine er tablet (extended-release)
pharmascience inc - nifedipine - tablet (extended-release) - 20mg - nifedipine 20mg - dihydropyridines
nifedipine er tablet (extended-release)
pro doc limitee - nifedipine - tablet (extended-release) - 20mg - nifedipine 20mg - dihydropyridines
ag-nifedipine er tablet (extended-release)
angita pharma inc. - nifedipine - tablet (extended-release) - 60mg - nifedipine 60mg - dihydropyridines
m-nifedipine er tablet (extended-release)
mantra pharma inc - nifedipine - tablet (extended-release) - 60mg - nifedipine 60mg - dihydropyridines
jamp nifedipine er tablet (extended-release)
jamp pharma corporation - nifedipine - tablet (extended-release) - 60mg - nifedipine 60mg - dihydropyridines
structolipid 200 mg/ml infusionsvätska, emulsion
inspra
pfizer australia pty ltd - eplerenone -
eplerenone an eplerenone 50 mg tablet blister pack
amneal pharma australia pty ltd - eplerenone -
espler eplerenone 25 mg tablet blister pack
arrotex pharmaceuticals pty ltd - eplerenone, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; hypromellose; magnesium stearate; macrogol 400; titanium dioxide; microcrystalline cellulose; polysorbate 80; iron oxide red; iron oxide yellow; purified talc; croscarmellose sodium - eplerenone is indicated: - to reduce the risk of cardiovascular death in combination with standard therapy in patients who have evidence of heart failure and left ventricular impairment within 3-14 days of an acute myocardial infarction (see clinical trials and dosage and administration). ; - to reduce the risk of cardiovascular mortality and morbidity in adult patients with nyha class ii (chronic) heart failure and left ventricular systolic dysfunction (lvef less than or equal to 30% or lvef less than or equal to 35% in addition to qrs duration of greater than 130 msec), in addition to standard optimal therapy (see clinical trials).